Zydus MD On Pipeline-In-A-Drug Approach, Partnering Intent

Plus Ibrance Generic

Zydus MD Sharvil Patel talks to Scrip about a pipeline-in-a-drug approach for novel molecules like ZYIL-1, the intent behind deals with Daewoong and LiqMeds and expected timelines for trial readouts of its PBC/NASH candidate saroglitazar

Patel Sharvil, Zydus Group
Zydus Group Managing Director Sharvil Patel Is Leading The Company's Growth In New Areas • Source: Zydus Lifesciences Ltd

Zydus Lifesciences Limited has been expanding the number of indications for which its novel molecules are being studied as it follows the "pipeline-in-a-drug" model successfully implemented by others like Abbott for Humira (adalimumab) and Sanofi and Regeneron Pharmaceuticals, Inc. for Dupixent (dupilumab).

While the approach has created multibillion-dollar drugs in developed economies like the US, in growing economies like India, where affordability...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip